Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PTEN: one gene, many syndromes.

Charis Eng1

  • 1Clinical Cancer Genetics Program and Human Cancer Genetics Program, Comprehensive Cancer Center, Division of Human Genetics, Department of Internal Medicine, The Ohio State University, Columbus, Ohio 43210, USA. eng-1@medctr.osu.edu

Human Mutation
|August 26, 2003
PubMed
Summary

Germline PTEN mutations are linked to Cowden syndrome and related disorders, increasing cancer risk. Understanding these PTEN mutations aids in managing cancer risks and developing targeted therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Embryonic stem cell factor FOXD3 (Genesis) defects in gastrointestinal stromal tumors.

Endocrine-related cancer·2023
Same author

A Randomized Trial Comparing the Effectiveness of Pre-test Genetic Counseling Using an Artificial Intelligence Automated Chatbot and Traditional In-person Genetic Counseling in Women Newly Diagnosed with Breast Cancer.

Annals of surgical oncology·2023
Same author

Development of webcam-collected and artificial-intelligence-derived social and cognitive performance measures for neurodevelopmental genetic syndromes.

American journal of medical genetics. Part C, Seminars in medical genetics·2023
Same author

Hemizygous variants in protein phosphatase 1 regulatory subunit 3F (PPP1R3F) are associated with a neurodevelopmental disorder characterized by developmental delay, intellectual disability and autistic features.

Human molecular genetics·2023
Same author

Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation.

Breast cancer research and treatment·2023
Same author

Integrating somatic CNV and gene expression in breast cancers from women with PTEN hamartoma tumor syndrome.

NPJ genomic medicine·2023

Area of Science:

  • Genetics and Molecular Biology
  • Oncology
  • Medical Genetics

Background:

  • PTEN gene mutations are implicated in several genetic syndromes, including Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), Proteus syndrome (PS), and Proteus-like syndrome (PSL).
  • CS is characterized by hamartomas and a high risk of breast, thyroid, and endometrial cancers.
  • BRRS, PS, and PSL were not previously associated with malignancy risk, but germline PTEN mutations suggest otherwise.

Purpose of the Study:

  • To investigate the association between germline PTEN mutations and malignancy risk in patients with BRRS, PS, and PSL.
  • To analyze genotype-phenotype correlations for PTEN mutations in CS and BRRS.
  • To explore mechanisms of PTEN inactivation in sporadic tumors.

Main Methods:

Related Experiment Videos

  • Analysis of germline PTEN mutations in patients with CS, BRRS, PS, and PSL.
  • Genotype-phenotype association studies comparing mutation locations with clinical manifestations.
  • Review of PTEN mutation frequencies and inactivation mechanisms in various sporadic cancers.

    • Main Results:

    • Germline PTEN mutations are found in a significant percentage of patients with CS, BRRS, PS, and PSL, suggesting similar cancer risks across these syndromes.
    • Specific PTEN mutation locations correlate with distinct clinical features, such as breast cancer development and multi-organ involvement.
    • Somatic PTEN mutations are frequent in endometrial carcinomas and glioblastoma multiforme, with tissue-specific inactivation mechanisms.

    Conclusions:

    • Germline PTEN mutations in BRRS, PS, and PSL indicate an elevated risk of malignancy, necessitating medical management similar to CS.
    • PTEN mutation analysis provides insights into cancer predisposition and potential therapeutic targets.
    • Novel mechanisms of PTEN inactivation, including altered subcellular localization and proteasomal degradation, warrant further investigation for therapeutic development.